Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction

Coronary Artery Disease

Volumn 21, Issue 6, 2010, Pages 330-335

  Ghaderian, Sayyed Mohammad Hossein ^a   Akbarzadeh Najar, Reza ^a   Tabatabaei Panah, Akram Sadat ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

acute myocardial infarction; gene polymorphism; matrix metalloproteinase; plasma levels

Indexed keywords

GELATINASE A; GELATINASE B; GENOMIC DNA; INTERSTITIAL COLLAGENASE; STROMELYSIN;

ACUTE HEART INFARCTION; ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; ENZYME BLOOD LEVEL; FAMILY HISTORY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBESITY; PRIORITY JOURNAL; SMOKING;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRAN; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; MYOCARDIAL INFARCTION; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS;

EID: 77955467884     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32833ce065     Document Type: Article

References (40)

1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657-671.
2. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91:2844-2850.
3. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102:1944-1949.
4. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89:201-210.
5. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002; 90:520-530.
6. Back M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010; 52:410-428.
7. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996; 271:13055-13060.
8. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998; 58:5321-5325.
9. Mizon-Gerard F, de Groote P, Lamblin N, Hermant X, Dallongeville J, Amouyel P, et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the etiology of left ventricular systolic dysfunction. Eur Heart J 2004; 25:688-693.
10. Nojiri T, Morita H, Imai Y, Maemura K, Ohno M, Ogasawara K, et al. Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol 2003; 92:181-186.
11. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 2002; 40:43-48.
12. Ye S,Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73:209-215.
13. Rauch I, Iglseder B, Paulweber B, Ladurner G, Strasser P. MMP-9 haplotypes and carotid artery atherosclerosis: an association study introducing a novel multicolor multiplex RealTime PCR protocol. Eur J Clin Invest 2008; 38:24-33.
14. Hettiaratchi A, Hawkins NJ, McKenzie G, Ward RL, Hunt JE, Wakefield D, Girolamo ND. The collagenase-1 (MMP-1) gene promoter polymorphism- 1607/2G is associated with favorable prognosis in patients with colorectal cancer. Br J Cancer 2007; 96:783-792.
15. Hojo Y, Ikeda U, Ueno S, Arakawa H, Shimada K. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J 2001; 65:71-75.
16. Quinones S, Saus J, Otani Y, Harris ED Jr, Kurkinen M. Transcriptional regulation of human stromelysin. J Biol Chem 1989; 264:8339-8344.
17. Buttice G, Quinones S, Kurkinen M. The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin gene. Nucleic Acids Res 1991; 19:3723-3731.
18. Borghaei RC, Sullivan C, Mochan E. Identification of a cytokine-induced repressor of interleukin-1 stimulated expression of stromelysin 1 (MMP-3). J Biol Chem 1999; 274:2126-2131.
19. Terashima M, Akita H, Kanazawa K, Inoue N, Yamada S, Ito K, et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999; 99:2717-2719.
20. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77:863-868.
21. Samnegard A, Silveira A, Lundman P, Boquist S, Odeberg J, Hulthe J, et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 -1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med 2005; 258:411-419.
22. White AJ, Duffy SJ,Walton AS, Ng JF, Rice GE, Mukherjee S, et al. Matrix metalloproteinase-3 and coronary remodelling: implications for unstable coronary disease. Cardiovasc Res 2007; 75:813-820.
23. Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, Kudo R, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res 1999; 59:4225-4227.
24. Welgus HG, Campbell EJ, Bar-Shavit Z, Senior RM, Teitelbaum SL. Human alveolar macrophages produce a fibroblast-like collagenase and collagenase inhibitor. J Clin Invest 1985; 76:219-224.
25. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T,Welgus HG, Alpers CE, Clowes AW. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995; 92:1393-1398.
26. Lemaitre V, O'Byrne TK, Borczuk AC, Okada Y, Tall AR, D'Armiento J. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 2001; 107:1227-1234.
27. Wesley RB II, Meng X, Godin D, Galis ZS. Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol 1998; 18:432-440.
28. Rocnik EF, Chan BM, Pickering JG. Evidence for a role of collagen synthesis in arterial smooth muscle cell migration. J Clin Invest 1998; 101:1889-1898.
29. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DP, Teepen H, van der Wal AC, Borst C. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000; 150:245-253.
30. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005; 85:1-31.
31. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86:515-581.
32. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 1991; 266:14064-14071.
33. Sudarsanam P, Winston F. The Swi/Snf family nucleosome-remodeling complexes and transcriptional control. Trends Genet 2000; 16:345-351.
34. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 2005; 15:490-495.
35. Couillard J, Demers M, Lavoie G, St-Pierre Y. The role of DNA hypomethylation in the control of stromelysin gene expression. Biochem Biophys Res Commun 2006; 342:1233-1239.
36. Chapman RE, Spinale FG. Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am J Physiol Heart Circ Physiol 2004; 286:H1-H10.
37. Ahmed SH, Clark LL, Pennington WR,Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113:2089-2096.
38. Langers AM, Sier CF, Hawinkels LJ, Kubben FJ, van DuijnW, van der Reijden JJ, et al. MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. Br J Cancer 2008; 98:1820-1823.
39. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99:1788-1794.
40. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107:1579-1585.